bupivacaine has been researched along with Endometrial Neoplasms in 2 studies
Bupivacaine: A widely used local anesthetic agent.
1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide : A piperidinecarboxamide obtained by formal condensation of the carboxy group of N-butylpipecolic acid with the amino group of 2,6-dimethylaniline.
bupivacaine : A racemate composed of equimolar amounts of dextrobupivacaine and levobupivacaine. Used (in the form of its hydrochloride hydrate) as a local anaesthetic.
Endometrial Neoplasms: Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We enrolled endometrial cancer patients undergoing open abdominal hysterectomy with lymphadenectomy by the same surgeon." | 1.40 | Multimodal pain control is associated with reduced hospital stay following open abdominal hysterectomy. ( Jennings, PW; Santoso, JT; Ulm, MA; Wan, JY, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Santoso, JT | 1 |
| Ulm, MA | 1 |
| Jennings, PW | 1 |
| Wan, JY | 1 |
| Mercadante, S | 1 |
| Villari, P | 1 |
| Ferrera, P | 1 |
| Arcuri, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multimodal Pain Management for Cesarean Delivery: A Randomized Control Trial[NCT02922985] | Phase 4 | 120 participants (Actual) | Interventional | 2016-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
This is the Apgar score of the newborn collected at 5 minutes. Range is from 0-10, with the higher scores meaning a better outcome. (NCT02922985)
Timeframe: 5 minutes after birth
| Intervention | score on a scale (Median) |
|---|---|
| Placebo Control Group | 9 |
| Multimodal Pain Regimen Group | 9 |
Time to discharge from hospital, measured in hours (NCT02922985)
Timeframe: From time of hospital admission to time of discharge home up to 168 hours.
| Intervention | hours (Median) |
|---|---|
| Placebo Control Group | 50.2 |
| Multimodal Pain Regimen Group | 50 |
neonate receipt of oxygen by nasal cannula or mechanical ventilation (NCT02922985)
Timeframe: after birth and before hospital discharge
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo Control Group | 0 |
| Multimodal Pain Regimen Group | 4 |
Rate of admission to the neonatal intensive care unit (NCT02922985)
Timeframe: after birth and before hospital discharge
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo Control Group | 2 |
| Multimodal Pain Regimen Group | 6 |
Number of opioid pain tablets remaining on post-operative day #7 from hospital discharge as reported by patients (NCT02922985)
Timeframe: 7 days post delivery
| Intervention | Tablets (Median) |
|---|---|
| Placebo Control Group | 18 |
| Multimodal Pain Regimen Group | 19 |
Pain Score at 24 Hours Post Operatively, expressed on a pain scale from 0-10 with the higher score meaning worse pain (outcome). (NCT02922985)
Timeframe: 24 hours post-operatively
| Intervention | score on a scale (Median) |
|---|---|
| Placebo Control Group | 5 |
| Multimodal Pain Regimen Group | 6 |
Pain Score at 48 Hours Post-operatively, expressed on a pain scale from 0-10 with the higher score meaning worse pain (outcome). (NCT02922985)
Timeframe: 48 hours post-operatively
| Intervention | score on a scale (Median) |
|---|---|
| Placebo Control Group | 4 |
| Multimodal Pain Regimen Group | 3 |
Pain score at 6-12 hours post-operatively, expressed on a pain scale from 0-10 with the higher score meaning worse pain (outcome). (NCT02922985)
Timeframe: 6-12 hours post-operatively
| Intervention | score on a scale (Median) |
|---|---|
| Placebo Control Group | 6 |
| Multimodal Pain Regimen Group | 6 |
Time, in hours, to first administration of opioid pain medication post operatively (NCT02922985)
Timeframe: 48 hours post cesarean delivery
| Intervention | hours (Median) |
|---|---|
| Placebo Control Group | 6.05 |
| Multimodal Pain Regimen Group | 6.35 |
Every opioid intake by the patient in the first 48 hours after CD will be recorded and quantified in morphine milligram equivalents (NCT02922985)
Timeframe: 48 hours post cesarean delivery
| Intervention | morphine milligram equivalents (Median) |
|---|---|
| Placebo Control Group | 42 |
| Multimodal Pain Regimen Group | 49.5 |
2 other studies available for bupivacaine and Endometrial Neoplasms
| Article | Year |
|---|---|
Multimodal pain control is associated with reduced hospital stay following open abdominal hysterectomy.
Topics: Acetaminophen; Adolescent; Adult; Aged; Aged, 80 and over; Amines; Analgesics; Bupivacaine; Cohort S | 2014 |
Local anesthetic switching for intrathecal tachyphylaxis in cancer patients with pain.
Topics: Adult; Anesthetics, Local; Bupivacaine; Carcinoma, Small Cell; Endometrial Neoplasms; Female; Humans | 2003 |